NRx Pharmaceuticals (NRXP) Provides Business Update, Reports Q2, Focuses on Reactivation & Advancement of Psychiatry Franchise

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. META
8. N2EW34
9. INTC
10. IMNN

Go back to NRx Pharmaceuticals (NRXP) Provides Business Update, Reports Q2, Focuses on Reactivation & Advancement of Psychiatry Franchise

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss of $0.10

August 15, 2022 7:16 AM EDT

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported Q2 EPS of ($0.10), versus ($4.34) reported last year.

As of June 30, 2022, cash was $24.5 million compared to $27.6 million as of December 31, 2021. They believe that they have sufficient funds and if necessary, the ability to reduce expenditures, to support... More